New research shows that ixabepilone together with bevacizumab (IXA + BEV) is a well-tolerated, effective combination in the treatment of platinum-resistant ovarian cancer / taxanes. The use of the combination IXA + BEV gave better results in both progression-free time and overall survival than using only ixabepilone
A study by scientists from the Yale Cancer Center and the University of Maryland Comprehensive Cancer Center shows that ixabepilone together with bevacizumab (IXA + BEV) is a well-tolerated, effective combination in the treatment of ovarian cancer platinum/taxane resistant, giving better therapeutic effects than with the use of ixabepilone alone. The results indicate that using the combination can significantly extend both progression-free and overall survival. The results were published in British Journal of Cancer .
"New approaches to recurrent ovarian cancer are very much need...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
